GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Solasia Pharma KK (TSE:4597) » Definitions » Debt-to-EBITDA

Solasia Pharma KK (TSE:4597) Debt-to-EBITDA : -0.07 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Solasia Pharma KK Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Solasia Pharma KK's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円33.0 Mil. Solasia Pharma KK's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円27.0 Mil. Solasia Pharma KK's annualized EBITDA for the quarter that ended in Dec. 2023 was 円-916.0 Mil. Solasia Pharma KK's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.07.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Solasia Pharma KK's Debt-to-EBITDA or its related term are showing as below:

TSE:4597' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.09   Med: -0.09   Max: -0.02
Current: -0.1

During the past 11 years, the highest Debt-to-EBITDA Ratio of Solasia Pharma KK was -0.02. The lowest was -4.09. And the median was -0.09.

TSE:4597's Debt-to-EBITDA is ranked worse than
100% of 660 companies
in the Drug Manufacturers industry
Industry Median: 1.705 vs TSE:4597: -0.10

Solasia Pharma KK Debt-to-EBITDA Historical Data

The historical data trend for Solasia Pharma KK's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solasia Pharma KK Debt-to-EBITDA Chart

Solasia Pharma KK Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.29 -0.04 -0.02 -0.09

Solasia Pharma KK Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.19 -0.25 -0.09 -0.07

Competitive Comparison of Solasia Pharma KK's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Solasia Pharma KK's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Solasia Pharma KK's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Solasia Pharma KK's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Solasia Pharma KK's Debt-to-EBITDA falls into.



Solasia Pharma KK Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Solasia Pharma KK's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(33 + 27) / -635
=-0.09

Solasia Pharma KK's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(33 + 27) / -916
=-0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Solasia Pharma KK  (TSE:4597) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Solasia Pharma KK Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Solasia Pharma KK's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Solasia Pharma KK (TSE:4597) Business Description

Traded in Other Exchanges
Address
2-1-1 Shiba Park, 4th Floor, Sumitomo Real Estate Shiba Park Tower, Minato-ku, Tokyo, JPN, 105-0011
Solasia Pharma KK develops and distributes pharmaceuticals and medical devices relating to malignant tumors.

Solasia Pharma KK (TSE:4597) Headlines

No Headlines